Pulmonary Exacerbation

Among patients with non-cystic fibrosis bronchiectasis, once-daily brensocatib for 52 weeks lowered the annualized pulmonary exacerbation rate and was well tolerated, according to topline results from the ASPEN trial.

Among patients with bronchiectasis, disease severity was higher with a blood eosinophil count less than 50 cells/L or higher than 300 cells/L, according to results published in CHEST.

WASHINGTON — Among children with asthma, poor disease control was linked to receipt of food stamps and trouble affording medication, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Showing more improvement in bronchodilator responsiveness testing was linked to more exacerbations, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

In patients aged 6 to 21 years with cystic fibrosis receiving pulmonary exacerbation treatment, changing antibiotics was not clinically beneficial, according to results published in Annals of the American Thoracic Society.

Patients with moderate to severe type 2 asthma, poor asthma control and high sleep disturbance experienced fewer nighttime symptoms and exacerbations with dupilumab, according to results published in Respiratory Medicine.

Adults with moderate to severe persistent asthma receiving rademikibart every 2 weeks showed greater improvements in lung function at week 12 compared with patients assigned placebo, according to topline results from a phase 2b trial.

Receipt of 4D-710, an aerosolized gene therapy, resulted in high cystic fibrosis transmembrane conductance regulator protein expression levels in patients with cystic fibrosis, according to a company press release.

HONOLULU — Patients with non-cystic fibrosis bronchiectasis and persistent Aspergillus fumigatus faced a heightened risk for exacerbations, according to research presented at the CHEST Annual Meeting.

Patients with bronchiectasis who produced discolored sputum appeared more likely to experience exacerbations, hospitalization and death, according to a poster presented at the European Respiratory Society International Congress.